Overview

• Results were presented at the IASLC 2025 World Conference on Lung Cancer on September 8.
• The randomized phase III study enrolled 530 patients across 16 hospitals in China to compare HypoRT (45 Gy in 15 fractions over 3 weeks) with ConvRT (60 Gy in 30 fractions over 6 weeks), both given with platinum–etoposide chemotherapy.
• After a median follow-up of 43.4 months, median overall survival was 40.2 months with HypoRT versus 47.9 months with ConvRT (HR 1.04; 95% CI 0.81–1.33), and progression-free survival was similar.
• Severe treatment-related adverse events were lower with HypoRT, with acute grade ≥3 events in 48.7% versus 67.7% for ConvRT, including reduced hematologic toxicity, lymphopenia, and radiation pneumonitis.
• The shortened three-week schedule offers potential benefits for patient convenience and resource use, and investigators recommend external validation and studies combining HypoRT with immune checkpoint inhibitors.